Due to mutually exclusive MYST1 interactions, both complexes act opposite to each other (MYST1–p65–SIRT1 act as a repressor complex, while MYST1–p65–AR as an activator complex), controlling the acetylation of lysine 16 on histone H4 (H4K16Ac) involved in the regulation of cancer progression. Here, KAT8 is linked to cancer.